Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders

Volume: 22, Issue: 18, Pages: 2445 - 2454
Published: Aug 9, 2021
Abstract
Introduction: Insomnia is common among children and adolescents with Autism spectrum disorder (ASD). The first drug licensed for insomnia in this population, a pediatric-appropriate prolonged-release melatonin (PedPRM) formulation is described.Areas covered: Literature search on PedPRM efficacy and safety profile in clinical trials, and a proposed decision-making algorithm to optimize outcome in the treatment of insomnia in children and...
Paper Details
Title
Pediatric prolonged-release melatonin for insomnia in children and adolescents with autism spectrum disorders
Published Date
Aug 9, 2021
Volume
22
Issue
18
Pages
2445 - 2454
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.